HomeCompareTFFP vs GIS

TFFP vs GIS: Dividend Comparison 2026

TFFP yields 3076.92% · GIS yields 6.55%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TFFP wins by $578804600665.42M in total portfolio value
10 years
TFFP
TFFP
● Live price
3076.92%
Share price
$0.07
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$578804600665.50M
Annual income
$544,023,840,488,516,100.00
Full TFFP calculator →
GIS
GIS
● Live price
6.55%
Share price
$37.11
Annual div
$2.43
5Y div CAGR
22.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$79.2K
Annual income
$16,311.42
Full GIS calculator →

Portfolio growth — TFFP vs GIS

📍 TFFP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTFFPGIS
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TFFP + GIS cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TFFP pays
GIS pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TFFP
Annual income on $10K today (after 15% tax)
$261,538.46/yr
After 10yr DRIP, annual income (after tax)
$462,420,264,415,238,660.00/yr
GIS
Annual income on $10K today (after 15% tax)
$556.59/yr
After 10yr DRIP, annual income (after tax)
$13,864.71/yr
At 15% tax rate, TFFP beats the other by $462,420,264,415,224,770.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TFFP + GIS for your $10,000?

TFFP: 50%GIS: 50%
100% GIS50/50100% TFFP
Portfolio after 10yr
$289402300332.79M
Annual income
$272,011,920,244,266,200.00/yr
Blended yield
93.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on TFFP right now

TFFP
Analyst Ratings
5
Buy
Consensus: Buy
Altman Z
-34.6
Piotroski
3/9
GIS
Analyst Ratings
9
Buy
19
Hold
6
Sell
Consensus: Hold
Price Target
$47.42
+27.8% upside vs current
Range: $35.00 — $63.00
Altman Z
2.2
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TFFP buys
0
GIS buys
0
No recent congressional trades found for TFFP or GIS in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTFFPGIS
Forward yield3076.92%6.55%
Annual dividend / share$2.00$2.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%22.8%
Portfolio after 10y$578804600665.50M$79.2K
Annual income after 10y$544,023,840,488,516,100.00$16,311.42
Total dividends collected$576403114825.48M$51.1K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyHold

Year-by-year: TFFP vs GIS ($10,000, DRIP)

YearTFFP PortfolioTFFP Income/yrGIS PortfolioGIS Income/yrGap
1← crossover$318,392$307,692.31$11,504$804.11+$306.9KTFFP
2$9,496,461$9,155,781.67$13,371$1,061.65+$9.48MTFFP
3$265,378,974$255,217,760.17$15,723$1,416.15+$265.36MTFFP
4$6,949,441,440$6,665,485,937.77$18,735$1,911.16+$6949.42MTFFP
5$170,564,997,752$163,129,095,411.51$22,660$2,613.51+$170564.98MTFFP
6$3,924,365,658,393$3,741,861,110,798.54$27,874$3,627.81+$3924365.63MTFFP
7$84,659,703,250,880$80,460,631,996,399.20$34,947$5,121.52+$84659703.22MTFFP
8$1,712,795,370,094,185$1,622,209,487,615,743.00$44,762$7,369.21+$1712795370.05MTFFP
9$32,505,383,342,974,930$30,672,692,296,974,148.00$58,728$10,832.80+$32505383342.92MTFFP
10$578,804,600,665,499,400$544,023,840,488,516,100.00$79,151$16,311.42+$578804600665.42MTFFP

TFFP vs GIS: Complete Analysis 2026

TFFPStock

TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's lead drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It is also developing other dry powder products, such as cannabidiol substance for the treatment of various epilepsy syndromes, as well as anxiety, insomnia, and various pain; Inhaled SARS-CoV2 Monoclonal Antibody for the treatment of patients with COVID-19 infections; Niclosamide Inhalation Powder to treat tapeworm infections in humans, as well as COVID-19 disease; and other vaccines. The company has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs; a joint development agreement with Augmenta Bioworks, Inc. to develop inhaled SARS-CoV2 monoclonal antibody; and a licensing and collaboration agreement with UNION therapeutics A/S. The company was incorporated in 2018 and is based in Austin, Texas.

Full TFFP Calculator →

GISConsumer Staples

General Mills, Inc. manufactures and markets branded consumer foods worldwide. The company operates in five segments: North America Retail; Convenience Stores & Foodservice; Europe & Australia; Asia & Latin America; and Pet. It offers ready-to-eat cereals, refrigerated yogurt, soup, meal kits, refrigerated and frozen dough products, dessert and baking mixes, bakery flour, frozen pizza and pizza snacks, snack bars, fruit and salty snacks, ice cream, nutrition bars, wellness beverages, and savory and grain snacks, as well as various organic products, including frozen and shelf-stable vegetables. It also supplies branded and unbranded food products to the North American foodservice and commercial baking industries; and manufactures and markets pet food products, including dog and cat food. The company markets its products under the Annie's, Betty Crocker, Bisquick, Blue Buffalo, Blue Basics, Blue Freedom, Bugles, Cascadian Farm, Cheerios, Chex, Cinnamon Toast Crunch, Cocoa Puffs, Cookie Crisp, EPIC, Fiber One, Food Should Taste Good, Fruit by the Foot, Fruit Gushers, Fruit Roll-Ups, Gardetto's, Go-Gurt, Gold Medal, Golden Grahams, Häagen-Dazs, Helpers, Jus-Rol, Kitano, Kix, Lärabar, Latina, Liberté, Lucky Charms, Muir Glen, Nature Valley, Oatmeal Crisp, Old El Paso, Oui, Pillsbury, Progresso, Raisin Nut Bran, Total, Totino's, Trix, Wanchai Ferry, Wheaties, Wilderness, Yoki, and Yoplait trademarks. It sells its products directly, as well as through broker and distribution arrangements to grocery stores, mass merchandisers, membership stores, natural food chains, e-commerce retailers, commercial and noncommercial foodservice distributors and operators, restaurants, convenience stores, and pet specialty stores, as well as drug, dollar, and discount chains. The company operates 466 leased and 392 franchise ice cream parlors. General Mills, Inc. was founded in 1866 and is headquartered in Minneapolis, Minnesota.

Full GIS Calculator →
📬

Get this TFFP vs GIS comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TFFP vs SCHDTFFP vs JEPITFFP vs OTFFP vs KOTFFP vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.